Showing 1 - 6 results of 6 for search 'Axel Grothey', query time: 0.03s Refine Results
  1. 1
    Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer

    Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer by Pashtoon Murtaza Kasi, Gita Thanarajasingam, Heidi D. Finnes, Jose C. Villasboas Bisneto, Joleen M. Hubbard, Axel Grothey

    Published 2015-01-01
    Get full text
    Article
  2. 2
    BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer

    BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer by Scott Kopetz, Axel Grothey, Shifra Krinshpun, Meenakshi Malhotra, Paul Billings, Angel Rodriguez, Alexey Aleshin, Sarah Sawyer, Michelle Munro, Pashtoon Murtaza Kasi, Jessica Guilford, Sascha Ellers, Jacob Wulff, Nicole Hook, Allyson Koyen Malashevich, Solomon Moshkevich

    Published 2021-09-01
    Get full text
    Article
  3. 3
    HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01

    HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY... by Salvatore Siena, Kanwal Raghav, Toshiki Masuishi, Kensei Yamaguchi, Tomohiro Nishina, Elena Elez, Javier Rodriguez, Ian Chau, Maria Di Bartolomeo, Hisato Kawakami, Fumitaka Suto, Makito Koga, Koichiro Inaki, Yusuke Kuwahara, Issey Takehara, Daniel Barrios, Kojiro Kobayashi, Axel Grothey, Takayuki Yoshino

    Published 2024-11-01
    Get full text
    Article
  4. 4
    Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01

    Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomark... by Salvatore Siena, Kanwal Raghav, Toshiki Masuishi, Kensei Yamaguchi, Tomohiro Nishina, Elena Elez, Javier Rodriguez, Ian Chau, Maria Di Bartolomeo, Hisato Kawakami, Fumitaka Suto, Makito Koga, Koichiro Inaki, Yusuke Kuwahara, Issey Takehara, Daniel Barrios, Kojiro Kobayashi, Axel Grothey, Takayuki Yoshino

    Published 2025-01-01
    Get full text
    Article
  5. 5
    Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

    Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer by Takayuki Yoshino, Maria Di Bartolomeo, Kanwal Raghav, Toshiki Masuishi, Fotios Loupakis, Hisato Kawakami, Kensei Yamaguchi, Tomohiro Nishina, Zev Wainberg, Elena Elez, Javier Rodriguez, Marwan Fakih, Fortunato Ciardiello, Kapil Saxena, Kojiro Kobayashi, Emarjola Bako, Yasuyuki Okuda, Gerold Meinhardt, Axel Grothey, Salvatore Siena, DESTINY-CRC01 investigators

    Published 2023-06-01
    Get full text
    Article
  6. 6
    Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients

    Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients by Alberto Puccini, Andreas Seeber, Joanne Xiu, Richard M. Goldberg, Davide Soldato, Axel Grothey, Anthony F. Shields, Mohamed E. Salem, Francesca Battaglin, Martin D. Berger, Wafik S. El-Deiry, Ryuma Tokunaga, Madiha Naseem, Wu Zhang, Sukeshi Patel Arora, Moh’d M. Khushman, Michael J. Hall, Philip A. Philip, John L. Marshall, W. Michael Korn, Heinz-Josef Lenz

    Published 2021-10-01
    Get full text
    Article

Search Tools: